MedTrace Logo

Platelet Rich Plasma (PRP) for Facet Mediated Lumbar Low Back Pain

NCT04822753 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 91

Last updated 2025-07-11

No results posted yet for this study

Summary

Low back pain (LBP) is both the single most common cause of disability and the leading cause of visits when military personnel go to their primary care doctors. Military personnel that deal with LBP can often be placed on limited duty profile. Not surprisingly, the direct and indirect costs of low back and neck pain accounts for approximately $88 billion of health care expenditure. In order to reduce the large financial and personal cost, clinical studies must be designed to treat LBP. This study will provide evidence-based medicine on a new regenerative medicine treatment option that may significantly affect military personnel with LBP. PRP (Platelet Rich Plasma) may offer alternate treatment methods that may help preserve the facet joint structures, and improve pain and function without causing destructive lesions or worsening degenerative joints. This healing process may favor improved participation with rehabilitation therapy and ultimately improve return to duty status. This study will also assess the effectiveness of point of care generated PRP, as a minimally invasive treatment option for treating lumbar facet pain. Specifically, PRP effectiveness will be compared to injecting placebo control when injected into facet joints.

Conditions

  • Facet Joint Pain; Low Back Pain

Interventions

PROCEDURE

Platelet Rich Plasma injection to the lumbar facet joint

Using standard fluoroscopic view, place a needle at the target facet joint. Inject about 1ml of study injectate.

Sponsors & Collaborators

  • Uniformed Services University of the Health Sciences

    collaborator FED

  • The Geneva Foundation

    collaborator OTHER

  • Womack Army Medical Center

    lead FED

Principal Investigators

  • Min Ho Chang, MD · Womack Army Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-29
Primary Completion
2025-06-23
Completion
2025-06-23

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04822753 on ClinicalTrials.gov